A multicenter phase II study of glofitamab plus polatuzumab-R-CHP for patients with diffuse large B-cell lymphoma.

Glofitamab combined with pola-R-CHP achieves a 95% complete response rate in newly diagnosed diffuse large B-cell lymphoma patients.

• Why it matters: Effective treatments with durable responses are critical for DLBCL, especially in high-risk patients, and current options need improvement in response rates and safety profiles.
• What they did: A phase II trial enrolled 41 patients, administering two cycles of pola-R-CHP, then adding glofitamab from cycles 3 to 6, followed by monotherapy in cycles 7 and 8, assessing response and safety.
• The result: The regimen yielded a 95% CR rate, with 24-month PFS at 95%, low cytokine release syndrome incidence, and no neurotoxicity, supporting further clinical evaluation.